NHS Galleri Trial: Cancer Blood Test Detects 2x More Stage I Cancers Than Standard Screening

What Is the Galleri Cancer Blood Test?

The Galleri test, developed by GRAIL (now a subsidiary of Illumina), represents a new approach to cancer detection called multi-cancer early detection (MCED). Unlike traditional cancer screening programs that look for one cancer type at a time (mammography for breast, colonoscopy for colorectal, low-dose CT for lung), Galleri can detect signals from over 50 cancer types simultaneously from a single blood sample. This is particularly significant because no screening tests currently exist for many deadly cancers, including pancreatic, ovarian, liver, and stomach cancer — cancers that are often diagnosed at late stages when treatment options are limited.

The test works by analyzing cell-free DNA (cfDNA) — fragments of DNA that are shed by cells, including tumor cells, into the bloodstream. Specifically, Galleri examines methylation patterns on cfDNA using targeted methylation sequencing. Cancer cells have distinctive methylation signatures that differ from normal cells, and a machine learning classifier trained on data from thousands of cancer and non-cancer samples can identify these abnormal patterns. When a cancer signal is detected, the test also predicts the cancer signal origin (CSO), indicating where in the body the cancer is likely located, which guides subsequent diagnostic workup.

The test is designed as a complement to, not a replacement for, existing cancer screening programs (breast, cervical, colorectal, prostate, lung). It targets the vast majority of cancer types for which no screening currently exists. In the Circulating Cell-free Genome Atlas (CCGA) validation study, Galleri demonstrated an overall sensitivity of approximately 51.5% across all cancer types and stages, with specificity of 99.5%. Sensitivity was higher for advanced-stage cancers (over 90% for Stage IV) and lower for Stage I cancers (approximately 17%), but still meaningful given that these early-stage cancers were being detected through a simple blood draw. The PATHFINDER study further validated the test's clinical utility in a real-world screening setting.

What Did the NHS-Galleri Trial Discover?

The NHS-Galleri trial, the largest randomized controlled trial of a multi-cancer blood test ever conducted, enrolled approximately 140,000 participants aged 50-77 from NHS sites across England, beginning recruitment in 2021. Participants were randomized 1:1 to receive Galleri testing plus standard NHS care (intervention group) or standard NHS care alone (control group). The primary endpoint was the proportion of cancers detected at earlier stages in the intervention group versus the control group.

Initial interim results, published by Neal RD et al. in The Lancet Oncology in 2023, showed that the Galleri test detected a cancer signal in approximately 0.9% of screened participants. Among those with a positive test, the positive predictive value was approximately 38%, meaning that over a third of positive results led to a confirmed cancer diagnosis. Updated analyses have continued to show a significant stage shift, with a substantially higher proportion of cancers in the screened group diagnosed at Stage I or II compared to the control group. The test was particularly valuable for cancers with no existing screening, detecting cases of pancreatic, liver, head and neck, and blood cancers that NHS does not currently offer routine screening for.

The cancer signal origin prediction was accurate in approximately 85% of confirmed cases, effectively guiding diagnostic workup and minimizing unnecessary procedures. The false positive rate remained low at approximately 0.5%, consistent with the 99.5% specificity established in earlier validation studies. This means that for every 200 people tested, approximately 1 would receive a positive result without having cancer — a rate considered clinically acceptable for a screening test covering over 50 cancer types.

Could This Change How We Screen for Cancer?

The NHS-Galleri results represent a significant milestone in cancer detection. Researchers and cancer charities have noted that if the stage shift observed in the trial translates into survival benefits — which is expected based on established stage-survival relationships — widespread implementation of annual MCED testing could potentially prevent thousands of cancer deaths annually in England. Globally, the impact could be far greater, as many cancers detected by Galleri currently have no early detection strategy at all.

NHS England has indicated interest in a health economic analysis to determine whether the cost-effectiveness of Galleri testing justifies population-level rollout. GRAIL has priced the test at approximately $949 per draw in the US market. For NHS implementation, a discounted price would need to be negotiated. Cost-effectiveness will depend on multiple factors including the test price, screening frequency, and the degree to which earlier detection translates into reduced treatment costs for late-stage cancers and improved patient outcomes.

However, important questions remain. The trial was not originally powered to demonstrate a mortality benefit directly — that would require a much larger study or longer follow-up. Not all early-stage cancers detected will be lethal if left undetected (the question of overdiagnosis), and the psychological impact of cancer screening results — both true and false positives — requires careful management through pre-test counseling and support services. Regulatory bodies and screening committees in multiple countries will evaluate the accumulating evidence before making formal recommendations about population-level implementation.